GlassScriptPhysician profile
Crystal Lynne Mcdaniel
NPI 1750039053
$5,405.46
in general payments reported to CMS, 2019-2025
33 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,250 · 2023: $1,430 · 2024: $1,416 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.98 |
| Education | $151.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,010.63 | 2022-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $824.41 | 2023-2025 | |
| Glaxosmithkline, LLC. | $516.03 | 2022-2025 | Shingrix, Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $289.88 | 2022-2023 | Dupixent |
| Axsome Therapeutics, INC. | $270.67 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $239.60 | 2024-2025 | Veozah |
| Ardelyx, INC. | $219.89 | 2025 | Ibsrela |
| Amgen INC. | $216.78 | 2022 | |
| Novo Nordisk INC | $192.29 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $150.39 | 2024 | Voquezna |
| Abbott Laboratories | $144.13 | 2024-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Urovant Sciences INC | $125.00 | 2022 | |
| Kyowa Kirin, INC. | $125.00 | 2025 | |
| Mannkind Corporation | $117.64 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $113.92 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Pfizer INC. | $86.67 | 2022-2025 | |
| Grifols USA, LLC | $77.40 | 2023 | Xembify |
| Axonics, INC. | $72.22 | 2022 | |
| Leo Pharma INC. | $64.88 | 2023 | Adbry |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Kestra Medical Technology Services, INC. | $49.34 | 2024 | Assure Wcd |
| Biocryst US Sales Co., LLC | $46.21 | 2022 | |
| Kaleo, INC. | $42.67 | 2023 | Auvi-Q |
| Incyte Corporation | $37.09 | 2022-2023 | Opzelura |
| Biohaven Pharmaceutical Holding Company LTD. | $34.78 | 2022 | |
| Corium, LLC | $32.13 | 2022 | |
| Corcept Therapeutics | $30.83 | 2025 | Korlym |
| Dexcom, INC. | $25.97 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $20.16 | 2023 | Xolair |
| Genzyme Corporation | $17.91 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.12 | 2023 | Cuvitru |
| Inogen, INC. | $6.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.